- A solid, growing medical monitoring device producer which keeps adding customers and new products fueling growth.
- Earnings are growing faster due to operational leverage and cash flows used to buy back shares.
- However, we still find the shares quite expensive. If you’re in, we suggest to keep it, but for new investors we would advise a better entry point.
Masimo Is Closing In On $1 Billion In Revenues
October 15th, 2018 · No Comments